Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

and low-dose Qnexa, respectively, compared to 2.1% in the placebo group (p<0.0001);
  • In the ITT-LOCF analysis, LS mean percent weight loss at week 56 was 10.9%* and 5.1%* for the top and low dose, respectively, as compared to 1.6% for the placebo group (p<0.0001);
  • Among patients who completed the top-dose course of treatment, 83.5% lost >/= 5%; 67.7% lost >/= 10%; and 48.1% lost >/= 15% of their baseline weight;
  • Categorical weight loss from baseline (ITT-LOCF) was:

  • >/= 5%

    >/= 10%

    >/= 15%Top dose

    67%*

    47%*

    32%*Low dose

    45%*

    19%*

    7%+Placebo

    17%

    7%

    3%*p<0.0001 vs placebo+p < 0.05 vs placeboA significantly greater number of patients completed one year of treatment in the Qnexa groups, top dose (66%) and low dose (61%), as compared to the placebo group (53%). The most commonly reported side effects were tingling, dry mouth, constipation and altered taste. Rates of serious adverse events were the same across treatment groups. Most adverse events were seen early in treatment and there was a low dropout rate due to adverse events, 16.0% and 11.3% for top and low dose, respectively, compared to 8.4% for placebo.

    About the EQUIP StudyThe EQUIP study included 1,267 severely obese patients (1,050 females and 217 males) with an overall mean age of 42.7 years; mean BMI of 42.0 kg/m2; and mean baseline weight of 256 pounds. Eligibility criteria included age 18-70 years; BMI >/= 35 kg/m2 (no upper limit); triglycerides </= 200 mg/dl with treatment of 0-1 lipid-lowering medication; BP </= 140/90mm Hg with treatment of <3 anti-hypertensive medications; and fasting serum glucose level </= 110 mg/dl.

    The study was a randomized, double-blind, placebo-controlled, 3-arm, prospective trial with patients randomized to receive once-a-day treatment with low-dose Qnexa, top-dose Qnexa or placebo.
    '/>"/>

    SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
    2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
    3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
    4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
    5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
    6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
    8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
    9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
    10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
    11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... NEW YORK , July 25, 2014  Smile ... selected to showcase their Virtual Surgery Simulator among ... 2014, which will take place in Washington, ... for the Performing Arts. "Smile Train ... BioDigital alongside the talented community of innovators in health ...
    (Date:7/25/2014)... GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to announce the ... LLC, an Illinois limited liability company ... medical marijuana licenses in the state of Illinois ... 20% equity interest in LaurelCo, LLC in exchange for licenses ... well as all technology related to the machines and to ...
    (Date:7/25/2014)...  Solanbridge Group Inc (OTC: SLNX) is pleased to ... Buzznbrewz.com and the Letter of Intent issued on July ... Purchase Agreement. Charles R. Shirley , ... have Mr. David Pecoraro and Buzznbrewz.com join ... private sector and developed a tremendous network of contacts ...
    Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
    ... Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... for the third quarter of 2009, which includes a ... primarily from strong cash collections related to prior period ... of $32.1 million for the comparable period in 2008, ...
    ... (Nasdaq: ROCM ) today announced operating results for its ... Company reported sales of $9,009,000 for the current quarter compared ... The Company reported a quarterly net loss of $229,000 or ... or $.03 per diluted share for the fourth quarter of ...
    Cached Medicine Technology:Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 2Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 3Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 4Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 7Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 8Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 9Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 10Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 12
    (Date:7/26/2014)... July 26, 2014 The European security ... at $1290 million in 2014, and it is expected ... of 6.16%. The report incorporates the factors that influence ... of growth rates and projected total expenditure. The report ... global markets. Apart from the general overview of the ...
    (Date:7/26/2014)... gas chromatography reagents report defines and segments the concerned market ... chromatography reagents market in Europe is valued at $ 314.8 ... $445.5 million by 2018, at a CAGR of 8.6 %, ... the European gas chromatography reagents market, to get an idea ... glimpse of the segmentation of gas chromatography reagents market in ...
    (Date:7/26/2014)... July 26, 2014 (HealthDay News) -- Pools can provide ... make themselves sick if they swallow too much chlorinated ... it,s common for little ones to get water in ... from a pool, despite warnings from their parents. ... harmless, it,s important for parents to realize that ingesting ...
    (Date:7/26/2014)... Dallas,Texas (PRWEB) July 26, 2014 “BRIC ... on the BRIC Sinuscopes market. The report provides value, ... average prices (in US dollars) within market segments – ... shares and distribution shares data for each of these ... market participants, pipeline products, and news and deals related ...
    (Date:7/26/2014)... Everett, WA (PRWEB) July 26, 2014 “Healthy ... important in keeping those pearly whites shining,” says Community Health ... Your Teeth Healthy ." , They believe that an integration ... keep people healthy and well. Because of this, they encourage ... but also with dentist . , “Children and adults ...
    Breaking Medicine News(10 mins):Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 4Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 5Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 5Health News:Don't Let Kids Drink Pool Water 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2
    ... Pa., Nov. 24 WPCS International,Incorporated (Nasdaq: ... services for,specialty communication systems and wireless infrastructure, has ... $9 million in,new contracts. The contracts include projects ... Office of Emergency Management, YMCA, Group,Health Tacoma, UPS, ...
    ... ARAY ), a global leader in the field of radiosurgery, ... 20th Annual Piper Jaffray,Health Care Conference in New York City, ... PST). , A live ... relations page of the Company,s Web site at http://www.accuray.com ...
    ... 24 According to a new survey released,today, the vast majority ... percent -- are not taking the most basic steps of determining ... test if they are at,risk or taking the appropriate actions as ... baseline among Americans on their level of awareness and,knowledge regarding type ...
    ... Fight Against AIDS with their "Love for Life" Limited Edition ... 24 ALDO, a global fashion footwear and accessories ... program of the global health organization Population Services International, continues ... bracelets. ALDO has given more than $10 million ...
    ... of Drugs with Broad Potential to Treat Life-Threatening Viral Infections-- ... Agent Bavituximab and Equivalent Antibodies Cured Lethal Viral Infections in ... Confirms PS is a ,Druggable, Target Common to a Number ... TUSTIN, Calif., Nov. 24 Peregrine Pharmaceuticals, Inc. (Nasdaq: ...
    ... Cepheid,(Nasdaq: CPHD ) today announced that ... its Xpert(TM) MRSA/SA Skin and Soft Tissue (SSTI) ... (MRSA) and,Staphylococcus aureus (SA, typically Methicillin-sensitive) in skin ... MRSA/SA SSTI test is expected to,empower Canadian physicians ...
    Cached Medicine News:Health News:WPCS Announces $9 Million in New Contracts 2Health News:Accuray Incorporated to Present at 20th Annual Piper Jaffray Health Care Conference 2Health News:New Survey Shows Majority of Americans Need to Take Proper Steps to Manage Diabetes Risk 2Health News:New Survey Shows Majority of Americans Need to Take Proper Steps to Manage Diabetes Risk 3Health News:New Survey Shows Majority of Americans Need to Take Proper Steps to Manage Diabetes Risk 4Health News:ALDO Supports World AIDS Day by Donating 100% of Proceeds for Newest 'ALDO Fights Aids' Product 2Health News:ALDO Supports World AIDS Day by Donating 100% of Proceeds for Newest 'ALDO Fights Aids' Product 3Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 2Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 3Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 4Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 5Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 6Health News:Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections 2Health News:Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections 3Health News:Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections 4
    Stainless steel bone clamp....
    Reduction Forceps with Points for precise reduction of bone fragments with minimal soft tissue contact....
    Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
    Straight double action bone cutting rongeur....
    Medicine Products: